PSA AT AGE 44-50 PREDICTS LONG-TERM RISK OF PROSTATE CANCER METASTASES IN AN UNSCREENED POPULATION

被引：0
|
作者：
Lilja, Hans
Cronin, Angel
Bjork, Thomas
Manjer, Jonas
Nilsson, Peter
Dahlin, Anders
Bjartell, Anders
Scardino, Peter
Ulmert, David
Vickers, Andrew
机构：
来源：
JOURNAL OF UROLOGY | 2010年 / 183卷 / 04期
关键词：
D O I：
10.1016/j.juro.2010.02.1573
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
1725
引用
收藏
页码：E666 / E666
页数：1
相关论文
共 50 条
  • [31] WHICH PATIENTS ARE AT REAL HIGH RISK FOR DYING FROM PROSTATE CANCER? A LONG-TERM FOLLOW-UP ANALYSIS ON HIGH RISK PROSTATE CANCER PATIENTS TREATED IN THE PSA ERA
    Briganti, Alberto
    Suardi, Nazareno
    Gallina, Andrea
    Da Pozzo, Luigi F.
    Roscigno, Marco
    Freschi, Massimo
    Cestari, Andrea
    Guazzoni, Giorgio
    Rigatti, Patrizio
    Montorsi, Francesco
    JOURNAL OF UROLOGY, 2009, 181 (04): : 270 - 270
  • [32] LONG-TERM PROSTATE- SPECIFIC ANTIGEN (PSA) CONTROL IN PROSTATE CANCER: CONTINUOUS DEGARELIX OR DEGARELIX FOLLOWING LEUPROLIDE
    Tombal, B.
    Schroeder, F.
    Miller, K.
    Van Der Meulen, E.
    Persson, B. E.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 335 - 335
  • [33] Long-term costs and survival of prostate cancer: a population-based study
    Brodszky, Valentin
    Varga, Peter
    Gimesi-Orszagh, Judit
    Fadgyas-Freyler, Petra
    Boncz, Imre
    Nyirady, Peter
    Riesz, Peter
    Baji, Petra
    Pentek, Marta
    Rencz, Fanni
    Gulacsi, Laszlo
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2017, 49 (10) : 1707 - 1714
  • [34] Long-term costs and survival of prostate cancer: a population-based study
    Valentin Brodszky
    Péter Varga
    Judit Gimesi-Országh
    Petra Fadgyas-Freyler
    Imre Boncz
    Péter Nyirády
    Péter Riesz
    Petra Baji
    Márta Péntek
    Fanni Rencz
    László Gulácsi
    International Urology and Nephrology, 2017, 49 : 1707 - 1714
  • [35] Risk of prostate cancer death in long-term users of warfarin: a population-based case–control study
    V. Tagalakis
    H. Tamim
    M. Blostein
    J. A. Hanley
    S. R. Kahn
    Cancer Causes & Control, 2013, 24 : 1079 - 1085
  • [36] Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study
    H-J Shih
    M-C Kao
    P-S Tsai
    Y-C Fan
    C-J Huang
    Prostate Cancer and Prostatic Diseases, 2017, 20 : 328 - 333
  • [37] Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study
    Shih, H-J
    Kao, M-C
    Tsai, P-S
    Fan, Y-C
    Huang, C-J
    PROSTATE CANCER AND PROSTATIC DISEASES, 2017, 20 (03) : 328 - 333
  • [38] Long-term durability of PSA failure-free survival after radiotherapy for localized prostate cancer
    Yock, TI
    Zietman, AL
    Shipley, WU
    Thakral, HK
    Coen, JJ
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (02): : 420 - 426
  • [39] Long-term outcomes of salvage radiotherapy for PSA-recurrent prostate cancer: validation of the stephenson nomogram
    Cory M. Hugen
    Anthony J. Polcari
    Marcus L. Quek
    Richard P. Garza
    Mary P. Fitzgerald
    Robert C. Flanigan
    World Journal of Urology, 2010, 28 : 741 - 744
  • [40] Post-radiotherapy two year PSA nadir as a predictor of long-term prostate cancer mortality
    Zelefsky, M. J.
    Yamada, Y.
    Park, J.
    Kollmeier, M.
    Cox, B.
    Venkatraman, E. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S287 - S287
12345